El Corte Inglés advances breast cancer research with new customised therapy project
What: El Corte Inglés is financing a customised therapy project for breast cancer, joining four other research initiatives it has supported over the past decade.
Why it is important: This commitment underscores El Corte Inglés's dedication to advancing breast cancer research and developing innovative treatments, particularly for patients with limited options. By funding these projects, the company contributes significantly to the fight against cancer and supports cutting-edge medical research.
El Corte Inglés continues its partnership with the Spanish Association Against Cancer by funding a new customised therapy project for HER2+ breast cancer. This phase I clinical trial, led by Dr. Julio Delgado, aims to evaluate the toxicity and effectiveness of ARI-HER2+ cells and design a new cell therapy drug. The company has pledged EUR 1 million over five years to support this study, which is primarily conducted at the Clinic Barcelona Comprehensive Cancer Center.
This initiative builds on previous projects funded by El Corte Inglés since 2014, focusing on various aspects of breast cancer treatment, including alternative therapies, precision medicine, hormonal therapy, and immunotherapy. The ongoing collaboration has resulted in significant advancements, such as the creation and validation of TIL products and the initiation of clinical trials.
The current project involves three Spanish institutions: Hospital Clinic Barcelona-IDIBAPS, Hospital 12 de Octubre in Madrid, and Clínica Universidad de Navarra. Researchers will test different drug doses to establish an effective treatment protocol. The Spanish Agency for Medicines and Healthcare Products has approved the new product and is expected to greenlight the clinical trial soon.
El Corte Inglés's sustained support for breast cancer research highlights its commitment to social responsibility and innovation in healthcare, aiming to provide new hope for patients through groundbreaking therapies.
